The iShares MSCI Ireland ETF is one of the smaller country-specific equity products in the iShares family, holding 32 securities with 950,000 shares outstanding. Its net assets total roughly 66 million. The fund tracks the MSCI All Ireland Capped Index (Net) and charges a 0.50 percent expense ratio, a figure that sits meaningfully above the typical single-country developed-market ETF fee. The underlying exposure is dominated by financials and consumer staples, with AIB Group holding a 19.3 percent weight. Bank of Ireland holds 14.9 percent, placing the two banks together near a third of the portfolio. The fund is not a high-conviction vehicle, and its case rests on the stability of the Irish economy rather than on any operational advantage.
The fund's 30-day SEC yield is 2.59 percent. The 12-month trailing yield is 2.37 percent, confirming that income rather than capital appreciation is the primary return driver. Two structural forces shape the investment case. The first is Ireland's economic architecture, which concentrates corporate tax revenue and export earnings in a narrow set of multinational pharmaceutical and technology firms that are not themselves index constituents. The second is the fund's own small scale and elevated fee, which together compress the return available to shareholders relative to the underlying index.
The product has no operational complexity. It is a passive fund, and its performance is a direct pass-through of the index less the annual fee. The investment case therefore reduces to three questions: whether the Irish equity market is reasonably valued, whether Ireland's economic and tax environment remains stable, and whether a 66 million dollar fund at a 0.50 percent fee is the most efficient vehicle for the exposure. The answers to those questions are mixed, and the fund sits in the middle of a reasonable value zone rather than at either extreme.